Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry

NCT03118037 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 182

Last updated 2024-12-16

No results posted yet for this study

Summary

SAGE is an observational post market registry with the objective of characterizing long term outcomes after treatment of uterine fibroids with the Sonata System in real world clinical practice settings.

Conditions

  • Uterine Fibroid

Interventions

DEVICE

Sonata System

Transcervical access for radiofrequency ablation of uterine fibroids

Sponsors & Collaborators

  • Gynesonics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2024-11-11
Completion
2024-11-11
FDA Device
Yes

Countries

  • Germany
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03118037 on ClinicalTrials.gov